Expertise in
52
conditions

Dr. Tarek I. Hassanein

Gastroenterology
27700 Medical Center Road, 
Mission Viejo, CA 
Accepting New Patients
Offers Telehealth
39 Years of Experience
Referral required
Before you request
Expertise in
52
conditions
27700 Medical Center Road, 
Mission Viejo, CA 

Overview

Tarek Hassanein is a Gastroenterologist practicing medicine in Mission Viejo, California. He has been practicing medicine for over 39 years.

Dr. Hassanein is highly rated in 52 conditions, according to our data. His clinical expertise encompasses Hepatitis C, Hepatitis, Non-Alcoholic Fatty Liver Disease, Endoscopy, and Liver Transplant.

Dr. Hassanein is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 83 peer reviewed articles and participating in 15 clinical trials. Dr. Hassanein is currently accepting new patients.

Specialties

Gastroenterology

Licenses

Internal Medicine in CA

Board Certifications

American Board Of Internal Medicine

Fellowships

University of Pittsburgh Medical Center , Hepatology , 1992 - 1994

Hospital Affiliations

Grossmont Hospital
Scripps Mercy Hospital
Sharp Coronado Hospital And Hlthcr Ctr
Sharp Chula Vista Medical Center
Hoag Memorial Hospital Presbyterian

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Group
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

27700 Medical Center Road, Mission Viejo, CA 92691

Additional Areas of Focus

Dr. Hassanein has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Drug
Study Drug: Volixibat
Study Phase: Phase 2
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Enrollment Status: Terminated
Publish Date: June 30, 2026
Intervention Type: Drug
Study Drug: Belapectin
Study Phase: Phase 2/Phase 3
A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 With Primary Biliary Cholangitis Who Are Unresponsive to UDCA and/or OCA
A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 With Primary Biliary Cholangitis Who Are Unresponsive to UDCA and/or OCA
Enrollment Status: Completed
Publish Date: March 10, 2026
Intervention Type: Drug
Study Drug: CNP-104
Study Phase: Phase 1/Phase 2
The HepQuant SHUNT Liver Diagnostic Kit for Likelihood of Large Esophageal Varices: The SHUNT-V Study
The HepQuant SHUNT Liver Diagnostic Kit for Likelihood of Large Esophageal Varices: The SHUNT-V Study
Enrollment Status: Completed
Publish Date: April 11, 2025
Intervention Type: Combination product
Study Phase: Not Applicable
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy
Enrollment Status: Terminated
Publish Date: January 09, 2024
Intervention Type: Drug
Study Phase: Phase 4
An Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and PK of MN-001 (Tipelukast) on HDL Function and Serum Triglyceride Levels in NASH and Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects With Hypertriglyceridemia
An Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and PK of MN-001 (Tipelukast) on HDL Function and Serum Triglyceride Levels in NASH and Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects With Hypertriglyceridemia
Enrollment Status: Completed
Publish Date: March 15, 2023
Intervention Type: Drug
Study Phase: Phase 2
An Open-Label, Two-Part, Phase 1/2a, Crossover Study to Determine the Absolute Bioavailability and Pharmacokinetics of Oral Immediate-Release Doses of OCR-002 in Subjects With Varying Degrees of Cirrhosis
An Open-Label, Two-Part, Phase 1/2a, Crossover Study to Determine the Absolute Bioavailability and Pharmacokinetics of Oral Immediate-Release Doses of OCR-002 in Subjects With Varying Degrees of Cirrhosis
Enrollment Status: Completed
Publish Date: September 20, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124
Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124
Enrollment Status: Withdrawn
Publish Date: August 30, 2021
Intervention Type: Drug, Device
Study Phase: Early Phase 1
View 9 Less Clinical Trials

83 Total Publications

A randomized, open-label, Phase 2a study to assess the safety, pharmacodynamics, and pharmacokinetics of YAQ007 versus rifaximin in cirrhosis.
A randomized, open-label, Phase 2a study to assess the safety, pharmacodynamics, and pharmacokinetics of YAQ007 versus rifaximin in cirrhosis.
Journal: Hepatology (Baltimore, Md.)
Published: December 04, 2025
Similar Doctors
Expertise in
23
conditions
Dr. Norah A. Terrault
Gastroenterology
Expertise in
23
conditions
Dr. Norah A. Terrault
Gastroenterology
Referral may be required

Los Angeles-Gi Liver Clinic

1510 San Pablo St Ste 200, 
Los Angeles, CA 
 (46.1 miles away)
323-442-8894
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Norah Terrault is a Gastroenterologist practicing medicine in Los Angeles, California. Dr. Terrault is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Hepatitis, Hepatitis C, Hepatitis B, Liver Transplant, and Hepato-Pancreato-Biliary Surgery.

Expertise in
50
conditions
Dr. Jason B. Samarasena
Gastroenterology
Expertise in
50
conditions
Dr. Jason B. Samarasena
Gastroenterology
Referral may be required

UCI Health Chao Family Comprehensive Digestive Disease Center

101 The City Drive South, Building 22C, 
Orange, CA 
 (20.3 miles away)
888-717-4463
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Jason Samarasena is a UCI Health physician who specializes in treating gastrointestinal disorders, including gastroesophageal reflux disease, esophageal disease, pancreatic cysts, biliary tract disorders, gastric intestinal metaplasia and colorectal cancer.His research interests include advanced endoscopic imaging, characterization and treatment of pancreatic cysts, confocal laser endomicroscopy, bowel preparation before colonoscopy, endoscopic mucosal resection and endoscopic submucosal dissection.Samarasena received his medical degree from Memorial University of Newfoundland, Canada, where he graduated on the Dean’s List. He completed both general gastroenterology and interventional endoscopy fellowships at UC Irvine.Press Ganey has named Samarasena as one of the top five physicians for patient satisfaction in the ambulatory surgery group at UCI Health. He was named the 2016 Teaching Attending of the Year by the UC Irvine Gastroenterology Fellowship. He is the current president of the Orange County GI Society.Nickname: Dr. Sam. Dr. Samarasena is highly rated in 50 conditions, according to our data. His clinical expertise encompasses Barrett Esophagus, Jaundice, Gastroesophageal Reflux Disease (GERD), Endoscopy, and Colonoscopy. Dr. Samarasena is board certified in American Board Of Internal Medicine - Gastroenterology.

Expertise in
15
conditions
Dr. William J. Sandborn
Gastroenterology
Expertise in
15
conditions
Dr. William J. Sandborn
Gastroenterology
Referral may be required
Before you request

UC San Diego Student Health SVC Pharmacy

9500 Gilman Dr, 
La Jolla, CA 
 (53.5 miles away)
858-657-6327
Languages Spoken:
English
See accepted insurances
Accepting New Patients

William Sandborn is a Gastroenterologist practicing medicine in La Jolla, California. Dr. Sandborn is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Crohn's Disease, Hemorrhagic Proctocolitis, Ulcerative Colitis, Endoscopy, and Colonoscopy. Dr. Sandborn is currently accepting new patients.

Frequently Asked Questions about Dr. Tarek I. Hassanein

How do I make an appointment with Dr. Tarek I. Hassanein?

You can book an appointment with Dr. Tarek I. Hassanein by calling their office at 949-364-1400. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Tarek I. Hassanein a top-rated expert for Hepatitis C?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Tarek I. Hassanein is classified as an Elite expert for Hepatitis C, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Tarek I. Hassanein specialize in?

While Dr. Tarek I. Hassanein is a Gastroenterology, they have specific expertise in Hepatitis C, Hepatitis, and Non-Alcoholic Fatty Liver Disease. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Tarek I. Hassanein participate in research or clinical trials?

Yes. Dr. Tarek I. Hassanein has published 83 articles and abstracts on conditions like Hepatitis C. You can view a list of Dr. Tarek I. Hassanein's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Tarek I. Hassanein accept my insurance?

Dr. Tarek I. Hassanein accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 949-364-1400 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hassanein's expertise for a condition
ConditionClose
View All 14 Distinguished Conditions
View All 33 Advanced Conditions
View All 65 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile